You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-MD-22-004: Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43/R44- Clinical Trial Optional)

    Release Date: 01-05-2022Open Date: 03-05-2022Due Date: 04-04-2022Close Date: 04-05-2022

    Background Over the years, there has been continued improvement of health for Americans with the introduction of medical and scientific advances. Despite notable health improvements for the population as a whole through technological advancement, there continues to be an alarming disproportionate burden of illness among persons from racial and ethnic minority and other population groups who exper ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-NS-22-033: Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection- Interventions from Small Businesses (U44 Clinical Trial Not Allowed)

    Release Date: 01-06-2022Open Date: 02-14-2022Due Date: 03-14-2022Close Date: 03-15-2022

    Purpose The purpose of this funding opportunity announcement (FOA) is to solicit applications for cerebroprotective intervention research projects from eligible U.S. small businesses to be tested in the NINDS Stroke Preclinical Assessment Network (SPAN).SPAN will support late-stage preclinical studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in rodent mode ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-DK-21-011: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-06-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia. NIDDK has long supported this area of resear ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-DK-21-012: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-19-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite clear progress made during the last 15 years on cellular transplantation for T1D, the most recent results demonstrate a long-term limited viability of engrafted islets and, as a result, limited insulin independence under different novel modalities of immunosuppressive (IS) regimens tested. In addition, even the most innovative IS regimens required for transplant survival still have signifi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease.? It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease. It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase I ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-DK-21-021: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-25-2021Open Date: 01-17-2022 Due Dates: Multiple Close Date: 10-07-2022

    Early identification of T1D risk and the onset of autoimmunity provides the basis for a variety of major ongoing studies seeking to prevent or delay the disease. Ongoing research on the natural history of the development of T1D in at risk neonates has shown that early identification of those at risk can foster early diagnosis of T1D and avoid life-threatening diabetic ketoacidosis (DKA). It is est ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. OSD221-001: Scene Geometry Aided Automatic Target Recognition (ATR) for Radar

    Release Date: 12-01-2021Open Date: 01-12-2022Due Date: 02-10-2022Close Date: 02-10-2022

    OUSD (R&E) MODERNIZATION PRIORITY: Artificial intelligence/machine learning (AI/ML), autonomy TECHNOLOGY AREA(S): Information systems, sensors, electronics OBJECTIVE: Develop and demonstrate synthetic aperture radar (SAR) ATR that reduces false alarm rates by incorporating modern artificial intelligence and geometry of the imaged area. DESCRIPTION: The focus of this research incorporat ...

    SBIRPhase I/Phase IIDepartment of DefenseNational Geospatial-Intelligence Agency
  10. OSD221-002: Automatic Labeling of Multiple Target Synthetic Aperture Radar (SAR) Imagery for Automatic Target Recognition (ATR)

    Release Date: 12-01-2021Open Date: 01-12-2022Due Date: 02-10-2022Close Date: 02-10-2022

    OUSD (R&E) MODERNIZATION PRIORITY: Artificial intelligence/machine learning (AI/ML), autonomy TECHNOLOGY AREA(S): Information systems; sensors; electronics OBJECTIVE: Develop novel algorithms for labeling multiple target classes in Synthetic Aperture Radar (SAR) imagery to expedite training of SAR Automatic Target Recognition (ATR) algorithms. DESCRIPTION: The focus of this research wi ...

    SBIRPhase I/Phase IIDepartment of DefenseNational Geospatial-Intelligence Agency
US Flag An Official Website of the United States Government